132 related articles for article (PubMed ID: 37820538)
1. The predictive value of
Yin X; Li J; Chen B; Liu K; Hu S
Lung Cancer; 2023 Dec; 186():107389. PubMed ID: 37820538
[TBL] [Abstract][Full Text] [Related]
2. Comprehensive
Cui Y; Lin Y; Zhao Z; Long H; Zheng L; Lin X
Front Immunol; 2022; 13():994917. PubMed ID: 36466929
[TBL] [Abstract][Full Text] [Related]
3. Dynamic
Chen ZY; Fu R; Tan XY; Yan LX; Tang WF; Qiu ZB; Qi YF; Li YF; Hou QY; Wu YL; Zhong WZ; Jiang BY
Thorac Cancer; 2022 Sep; 13(17):2524-2531. PubMed ID: 35822254
[TBL] [Abstract][Full Text] [Related]
4. The efficiency of
Tao X; Li N; Wu N; He J; Ying J; Gao S; Wang S; Wang J; Wang Z; Ling Y; Tang W; Zhang Z
Eur J Nucl Med Mol Imaging; 2020 May; 47(5):1209-1219. PubMed ID: 32043180
[TBL] [Abstract][Full Text] [Related]
5. Utility of
Zhuang F; Haoran E; Huang J; Wu J; Xu L; Zhang L; Li Q; Li C; Zhao Y; Yang M; Ma M; She Y; Chen H; Luo Q; Zhao D; Chen C
Lung Cancer; 2023 Apr; 178():20-27. PubMed ID: 36764154
[TBL] [Abstract][Full Text] [Related]
6. Efficacy evaluation of neoadjuvant immunotherapy plus chemotherapy for non-small-cell lung cancer: comparison of PET/CT with postoperative pathology.
Cheng Y; Chen ZY; Huang JJ; Shao D
Eur Radiol; 2023 Oct; 33(10):6625-6635. PubMed ID: 37515634
[TBL] [Abstract][Full Text] [Related]
7.
Wang S; Di S; Lu J; Xie S; Yu Z; Liang Y; Gong T
Thorac Cancer; 2023 Aug; 14(24):2338-2349. PubMed ID: 37424279
[TBL] [Abstract][Full Text] [Related]
8. Tertiary lymphoid structures combined with biomarkers of inflammation are associated with the efficacy of neoadjuvant immunochemotherapy in resectable non-small cell lung cancer: A retrospective study.
Xu F; Zhu H; Xiong D; Wang K; Dong Y; Li L; Yuan S
Thorac Cancer; 2024 Jan; 15(2):172-181. PubMed ID: 38057283
[TBL] [Abstract][Full Text] [Related]
9. The role of
Wang X; Yang W; Zhou Q; Luo H; Chen W; Yeung SJ; Zhang S; Gan Y; Zeng B; Liu Z; Feng S; Zhang X; Cheng C
Eur J Nucl Med Mol Imaging; 2022 Oct; 49(12):4241-4251. PubMed ID: 35732974
[TBL] [Abstract][Full Text] [Related]
10. [
Vos JL; Zuur CL; Smit LA; de Boer JP; Al-Mamgani A; van den Brekel MWM; Haanen JBAG; Vogel WV
Eur J Nucl Med Mol Imaging; 2022 May; 49(6):2010-2022. PubMed ID: 34957526
[TBL] [Abstract][Full Text] [Related]
11. The predictive value of
Mattoli MV; Massaccesi M; Castelluccia A; Scolozzi V; Mantini G; Calcagni ML
Radiat Oncol; 2017 Jan; 12(1):4. PubMed ID: 28057034
[TBL] [Abstract][Full Text] [Related]
12. FDG PET/CT for assessing the resectability of NSCLC patients with N2 disease after neoadjuvant therapy.
Kremer R; Peysakhovich Y; Dan LF; Guralnik L; Kagna O; Nir RR; Bar-Shalom R
Ann Nucl Med; 2016 Feb; 30(2):114-21. PubMed ID: 26613715
[TBL] [Abstract][Full Text] [Related]
13. Utility of
Chen X; Bai G; Zang R; Song P; Bie F; Huai Q; Li Y; Liu Y; Zhou B; Bie Y; Yang Z; Gao S
Transl Oncol; 2023 Sep; 35():101725. PubMed ID: 37421908
[TBL] [Abstract][Full Text] [Related]
14. A novel analytical approach for outcome prediction in newly diagnosed NSCLC based on [
Zhang L; Xu C; Zhang X; Wang J; Jiang H; Chen J; Zhang H
Eur Radiol; 2023 Mar; 33(3):1757-1768. PubMed ID: 36222865
[TBL] [Abstract][Full Text] [Related]
15. Predictive and Prognostic Role of Metabolic Response in Patients With Stage III NSCLC Treated With Neoadjuvant Chemotherapy.
Castello A; Toschi L; Rossi S; Finocchiaro G; Grizzi F; Mazziotti E; Qehajaj D; Rahal D; Lopci E
Clin Lung Cancer; 2020 Jan; 21(1):28-36. PubMed ID: 31409523
[TBL] [Abstract][Full Text] [Related]
16. (18)F-fluorodeoxyglucose positron emission tomography versus computed tomography in predicting histopathological response to epidermal growth factor receptor-tyrosine kinase inhibitor treatment in resectable non-small cell lung cancer.
van Gool MH; Aukema TS; Schaake EE; Rijna H; Codrington HE; Valdés Olmos RA; Teertstra HJ; van Pel R; Burgers SA; van Tinteren H; Klomp HM
Ann Surg Oncol; 2014 Sep; 21(9):2831-7. PubMed ID: 24845729
[TBL] [Abstract][Full Text] [Related]
17. 18F-FDG PET/CT of Non-Small Cell Lung Carcinoma Under Neoadjuvant Chemotherapy: Background-Based Adaptive-Volume Metrics Outperform TLG and MTV in Predicting Histopathologic Response.
Burger IA; Casanova R; Steiger S; Husmann L; Stolzmann P; Huellner MW; Curioni A; Hillinger S; Schmidtlein CR; Soltermann A
J Nucl Med; 2016 Jun; 57(6):849-54. PubMed ID: 26823566
[TBL] [Abstract][Full Text] [Related]
18. Clinical utility of [
Zhang L; E H; Huang J; Wu J; Li Q; Hou L; Li C; Dai C; Deng J; Yang M; Ma M; Ren Y; Luo Q; Zhao D; Chen C
Eur Radiol; 2023 Dec; 33(12):8564-8572. PubMed ID: 37464112
[TBL] [Abstract][Full Text] [Related]
19. Development and validation of a radiomics-based nomogram for predicting a major pathological response to neoadjuvant immunochemotherapy for patients with potentially resectable non-small cell lung cancer.
Liu C; Zhao W; Xie J; Lin H; Hu X; Li C; Shang Y; Wang Y; Jiang Y; Ding M; Peng M; Xu T; Hu A; Huang Y; Gao Y; Liu X; Liu J; Ma F
Front Immunol; 2023; 14():1115291. PubMed ID: 36875128
[TBL] [Abstract][Full Text] [Related]
20. Metabolic tumor heterogeneity analysis by F-18 FDG PET/CT predicts mediastinal lymph node metastasis in non-small cell lung cancer patients with clinically suspected N2.
Pahk K; Chung JH; Yi E; Kim S; Lee SH
Eur J Radiol; 2018 Sep; 106():145-149. PubMed ID: 30150037
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
